Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus

Translational Research

Volumn 162, Issue 5, 2013, Pages 287-296

  Enocsson, Helena ^a   Wetterö, Jonas ^a   Skogh, Thomas ^a   Sjöwall, Christopher ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATINE KINASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PREDNISOLONE; UROKINASE RECEPTOR;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY DAMAGE INDEX; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART INFARCTION; HUMAN; KIDNEY INJURY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; VIRUS INFECTION;

EID: 84886085766     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2013.07.003     Document Type: Article

References (58)

1. L.E. Muñoz, K. Lauber, M. Schiller, A.A. Manfredi, and M. Herrmann The role of defective clearance of apoptotic cells in systemic autoimmunity Nat Rev Rheumatol 6 2010 280 289
2. A. Hedberg, E.S. Mortensen, and O.P. Rekvig Chromatin as a target antigen in human and murine lupus nephritis Arthritis Res Ther 13 2011 R214
3. T. Skogh, and O. Stendahl Complement-mediated delay in immune complex clearance from the blood owing to reduced deposition outside the reticuloendothelial system Immunology 49 1983 53 59
4. A.G. Johansson, T. Løvdal, K.E. Magnusson, T. Berg, and T. Skogh Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats Hepatology 24 1996 169 175
5. J.M. Ahearn, C.C. Liu, A.H. Kao, and S. Manzi Biomarkers for systemic lupus erythematosus Transl Res 159 2012 326 342
6. S. Gaitonde, D. Samols, and I. Kushner C-reactive protein and systemic lupus erythematosus Arthritis Rheum 59 2008 1814 1820
7. Z. Rezaieyazdi, M. Sahebari, and M.R. Hatef Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus 20 2011 1494 1500
8. T. Nakayama, S. Sonoda, T. Urano, T. Yamada, and M. Okada Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases Clin Chem 39 1993 293 297
9. H. Enocsson, C. Sjöwall, T. Skogh, M.L. Eloranta, L. Rönnblom, and J. Wetterö Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 60 2009 3755 3760
10. M. Trendelenburg, M. Lopez-Trascasa, and E. Potlukova High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis Nephrol Dial Transplant 21 2006 3115 3121
11. D. Gladman, E. Ginzler, and C. Goldsmith The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus Arthritis Rheum 39 1996 363 369
12. M.H. Al-Maini, J.D. Mountz, and H.A. Al-Mohri Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus Lupus 9 2000 132 139
13. S.S. Lee, S. Singh, K. Link, and M. Petri High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus Semin Arthritis Rheum 38 2008 41 54
14. L.H. Li, W.X. Li, and O. Wu Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis Mol Biol Rep 36 2009 2047 2052
15. O.J. Rullo, J.M. Woo, and M.F. Parsa Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus Arthritis Res Ther 15 2013 R18
16. M. Thunø, B. Macho, and J. Eugen-Olsen suPAR: the molecular crystal ball Dis Markers 27 2009 157 172
17. T. Chavakis, S.M. Kanse, B. Yutzy, H.R. Lijnen, and K.T. Preissner Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes Blood 91 1998 2305 2312
18. S.M. Kanse, C. Kost, O.G. Wilhelm, P.A. Andreasen, and K.T. Preissner The urokinase receptor is a major vitronectin-binding protein on endothelial cells Exp Cell Res 224 1996 344 353
19. E.S. Barnathan, A. Kuo, and K. Kariko Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA Blood 76 1990 1795 1806
20. K.D. Wohn, S.M. Kanse, V. Deutsch, T. Schmidt, A. Eldor, and K.T. Preissner The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage Thromb Haemost 77 1997 540 547
21. T. Plesner, E. Ralfkiaer, and M. Wittrup Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue Am J Clin Pathol 102 1994 835 841
22. J.D. Vassalli, D. Baccino, and D. Belin A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase J Cell Biol 100 1985 86 92
23. A. Nykjaer, B. Møller, and R.F. Todd III Urokinase receptor: an activation antigen in human T lymphocytes J Immunol 152 1994 505 516
24. J.C. Kirchheimer, Y.H. Nong, and H.G. Remold IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes J Immunol 141 1988 4229 4234
25. T. Chavakis, A.K. Willuweit, F. Lupu, K.T. Preissner, and S.M. Kanse Release of soluble urokinase receptor from vascular cells Thromb Haemost 86 2001 686 693
26. C.E. Weckerle, D. Mangale, and B.S. Franek Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus Arthritis Rheum 64 2012 2947 2952
27. N. Sidenius, C.F. Sier, and F. Blasi Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo FEBS Lett 475 2000 52 56
28. K. Donadello, S. Scolletta, C. Covajes, and J.L. Vincent suPAR as a prognostic biomarker in sepsis BMC Med 10 2012 2
29. O. Slot, N. Brunner, H. Locht, P. Oxholm, and R.W. Stephens Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis Ann Rheum Dis 58 1999 488 492
30. H.W. Zimmermann, A. Koch, S. Seidler, C. Trautwein, and F. Tacke Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis Liver Int 32 2012 500 509
31. M.L. Berres, B. Schlosser, T. Berg, C. Trautwein, and H.E. Wasmuth Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection J Clin Gastroenterol 46 2012 334 338
32. C. Wei, S. El Hindi, and J. Li Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 2011 952 960
33. E.M. Tan, A.S. Cohen, and J.F. Fries The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1982 1271 1277
34. J.F. Fries, and H.R. Holman Systemic lupus erythematosus: a clinical analysis L.H. Smith, Major problems in internal medicine 1975 W.B. Saunders Philadelphia, PA 8 20
35. D.D. Gladman, D. Ibanez, and M.B. Urowitz Systemic lupus erythematosus disease activity index 2000 J Rheumatol 29 2002 288 291
36. B. Cederblad, S. Blomberg, H. Vallin, A. Perers, G.V. Alm, and L. Rönnblom Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells J Autoimmun 11 1998 465 470
37. J. Eugen-Olsen, O. Andersen, and A. Linneberg Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population J Intern Med 268 2010 296 308
38. E.S. Ford, W.H. Giles, G.L. Myers, N. Rifai, P.M. Ridker, and D.M. Mannino C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000 Clin Chem 49 2003 1353 1357
39. H. Enocsson, J. Wetterö, T. Skogh, and C. Sjöwall Limited value of soluble urokinase plasminogen activator receptor as a disease activity marker in patients with systemic lupus erythematosus Arthritis Rheum 63 2011 S556 S557
40. G. Toldi, B. Szalay, and G. Beko Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus Biomarkers 17 2012 758 763
41. O. Andersen, J. Eugen-Olsen, K. Kofoed, J. Iversen, and S.B. Haugaard Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy J Med Virol 80 2008 209 216
42. A. Koch, S. Voigt, and C. Kruschinski Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients Crit Care 15 2011 R63
43. S. Lyngbaek, T. Sehestedt, and J.L. Marott CRP and suPAR are differently related to anthropometry and subclinical organ damage Int J Cardiol 167 2013 781 785
44. P. Rahman, D.D. Gladman, M.B. Urowitz, D. Hallett, and L.S. Tam Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus Lupus 10 2001 93 96
45. D.D. Gladman, C.H. Goldsmith, and M.B. Urowitz The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison J Rheumatol 27 2000 373 376
46. O. Nived, A. Jönsen, A.A. Bengtsson, C. Bengtsson, and G. Sturfelt High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus J Rheumatol 29 2002 1398 1400
47. T. Stoll, B. Seifert, and D.A. Isenberg SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus Br J Rheumatol 35 1996 248 254
48. A. Voss, A. Green, and P. Junker Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort Scand J Rheumatol 27 1998 98 105
49. B. Liu, B. Zhang, and T. Wang Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy J Neurosci Res 88 2010 2747 2754
50. H.M. Zhou, A. Nichols, P. Meda, and J.D. Vassalli Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis EMBO J 19 2000 4817 4826
51. B.K. Pliyev Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87) Mol Cell Biochem 321 2009 111 122
52. B.K. Pliyev, and M.Y. Menshikov Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis Inflammation 33 2010 1 9
53. R.J. Maas, J.K. Deegens, and J.F. Wetzels Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28 2013 1041 1048
54. H. Trachtman, C. Wei, and J. Reiser Circulating factor in FSGS: a black sheep in the suPAR family? Pediatr Nephrol 28 2013 1151 1152
55. V. D'Mello, S. Singh, Y. Wu, and R.B. Birge The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells J Biol Chem 284 2009 17030 17038
56. Y.J. Park, G. Liu, Y. Tsuruta, E. Lorne, and E. Abraham Participation of the urokinase receptor in neutrophil efferocytosis Blood 114 2009 860 870
57. P. Briassouli, E.V. Komissarova, R.M. Clancy, and J.P. Buyon Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: implications in the pathogenesis of congenital heart block Circ Res 107 2010 374 387
58. P. Briassouli, D. Rifkin, R.M. Clancy, and J.P. Buyon Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-beta and potentiates fibrosis J Immunol 187 2011 5392 5401